Summary
Eighteen patients with disseminated malignant melanoma were treated with a combination of carboplatinum and cytosine arabinoside. There were 14 males and 4 females with median age of 51 years (range 36–68 years). We observed 4 complete responses (CR) and 3 partial responses (PR). Lung metastases, cutaneous and subcutaneous metastases responded more often, while liver and lymph node metastases did not respond. Two groups of toxicities were observed: gastrointestinal and hematological. Only nine grade 3 toxicities were observed. Response rates and low toxicity we observed during this study warrant its use for patients with disseminated malignant melanoma comparing it in a future studies with DTIC containing regimens.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Comis RL: DTIC (NSC-45388) in malignant melanoma: a perspective. Cancer Treat Rep 60:165–176, 1976
Constanza ME, Nathanson L, Schoenfeld D, Volter J, Colsky J, Regelson W, Cunningham T, Sedransk N: Results with methyl-CCNU and DTIC in metastatic melanoma. Cancer 40:1010–1015, 1977
Luikart SD, Kennealey GT, Kirkwood JM: Randomized phase III trial of vinblastine, bleomycine and cis-dichloro-diammine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol 2:164–168, 1984
Wittes RE, Wittes JT, Golbey RB: Combination chemotherapy in metastatic malignant melanoma. Cancer 41:415–421, 1978
Vorobiof DA, Sarli R, Falkson G: Combination chemotherapy with dacarbazine and vindesine in the treatment of metastatic malignant melanoma. Cancer Treat Rep 70:927–928, 1986
Al-Sarraf M, Fletcher W, Oishi N, Pugh R, Hewlett JS, Balducci L, McCracken J, Padilla F: Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: A Southwest Oncology Group study. Cancer Treat Rep 66:31–35, 1982
Karakousis CP, Getaz EP, Bjornsson S, Henderson S, Irequi M, Martinez L, Ospina J, Cavins J, Preisler H, Holyioke E, Holterman O: cis-dicholorodiammineplatinum (II) and DTIC in malignant melanoma. Cancer Treat Rep 63:2009–2010, 1979
National Cancer Institute of Canada Melanoma Group: Vinblastine, bleomycine and cis-platinum for the treatment of metastatic malignant melanoma. J Clin Oncol 2:131–134, 1984
Carey RW, Anderson JR, Green M Ellison RR Nathanson L, Kennedy BJ: Treatment of metastatic malignant melano- ma with vinblastine, dacarbazine and cisplatin: a report from the Cancer and Leukemia Group B. Cancer Treat Rep 70:329–331, 1986
DelPrete SA, Maurer LH, O'Donnell J, Forcier RJ, Le Marble P: Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in metastatic melanoma. Cancer Treat Rep 68:1403–1405, 1984
McClay EF, Mastrangelo MJ, Bellet RE, Berd D: Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 71:465–469, 1987
Oratz R, Sprenger JL, Green M, Blum R, Vernz JC, Muggia FM: Treatment of metastatic malignant melanoma with dacarbazine and cisplatin. Cancer Treat Rep 71:877–878, 1987
Leyvraz S, Ohuma T, Lassus M, Holland JF: Phase I study of carboplatin in patients with advanced cancer, intermitent intravenous bolus and 24-hour infusion. J Clin Oncol 3:1385–1392, 1985
Kern DH, Morgan CR, Hildebrand-Zenki SU: In vitro pharmacodynamics of 1-β-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum (II). Cancer Res 48:117–121, 1988
Mulder NH, Sleijfer DTh, de Vries EGE, Scgraffordt Koops H, Samson MJ, Willemse PHB: Phase II study of bleomycine, dacarbazine (DTIC) and vindesine in disseminated malignant melanoma. J Cancer Res Clin Oncol 115:93–95, 1989
Mulder NH, Sleijfer DTh, de Vries EGE, Schraffordt Koops H, Willemse PHB: Phase II study of carboplatin and cytosine arabinoside in patients with disseminated malignant melanoma. J Cancer Res Clin Oncol 116:301–302, 1990
Bajetta E, Verusio C, Bofante V, Bonadonna G: Cytarabine and cisplatin in advanced malignant melanoma. Cancer Treat Rep 70:1441–1442, 1986
Luce JK: Chemotherapy of malignant melanoma. Cancer 30:1604–1615, 1972
Berek JS, Knox R: Intraperitoneal cytosine arabinoside given prior to or with cisplatin results in synergy of survival in a murine ovarian carcinoma mode. Proc Soc Gynecol Invest 34:207, 1987
Davidson JP, Faber PJ, Fisher RG, Mansy S, Peresie HJ, Rosenberg B, Van Camp L: Platinum-pyramidine blue and related complexes: a new class of potent anti-tumor agents. Cancer Chemother Rep 59:287–290, 1975
Bergerat JP, Drewinko B, Corry P, Barlogie B, Ho DH: Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-β-D-arabinofuranosylcytosine. Cancer Res 41:25–30, 1981
Evans LM, Casper ES, Rosenbluth R: Phase II trial of carboplatinum in advanced malignant melanoma. Cancer Treat Rep 71:171–172, 1987
Casper ES, Bajorin D: Phase II trial of carboplatin in patients with advanced melanoma. Invest New Drugs 8:187–190, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jeremic, B., Djuric, L. & Mijatovic, L. Carboplatinum and cytosine arabinoside in patients with disseminated malignant melanoma. Invest New Drugs 9, 277–280 (1991). https://doi.org/10.1007/BF00176984
Issue Date:
DOI: https://doi.org/10.1007/BF00176984